These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

681 related articles for article (PubMed ID: 21552559)

  • 1. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.
    Hörnberg E; Ylitalo EB; Crnalic S; Antti H; Stattin P; Widmark A; Bergh A; Wikström P
    PLoS One; 2011 Apr; 6(4):e19059. PubMed ID: 21552559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of prostate cancer bone metastases according to expression levels of steroidogenic enzymes and androgen receptor splice variants.
    Jernberg E; Thysell E; Bovinder Ylitalo E; Rudolfsson S; Crnalic S; Widmark A; Bergh A; Wikström P
    PLoS One; 2013; 8(11):e77407. PubMed ID: 24244276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases.
    Zhang X; Morrissey C; Sun S; Ketchandji M; Nelson PS; True LD; Vakar-Lopez F; Vessella RL; Plymate SR
    PLoS One; 2011; 6(11):e27970. PubMed ID: 22114732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.
    Ylitalo EB; Thysell E; Jernberg E; Lundholm M; Crnalic S; Egevad L; Stattin P; Widmark A; Bergh A; Wikström P
    Eur Urol; 2017 May; 71(5):776-787. PubMed ID: 27497761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
    Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
    Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases.
    Kallio HML; Hieta R; Latonen L; Brofeldt A; Annala M; Kivinummi K; Tammela TL; Nykter M; Isaacs WB; Lilja HG; Bova GS; Visakorpi T
    Br J Cancer; 2018 Aug; 119(3):347-356. PubMed ID: 29988112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
    Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
    Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High levels of the AR-V7 Splice Variant and Co-Amplification of the Golgi Protein Coding YIPF6 in AR Amplified Prostate Cancer Bone Metastases.
    Djusberg E; Jernberg E; Thysell E; Golovleva I; Lundberg P; Crnalic S; Widmark A; Bergh A; Brattsand M; Wikström P
    Prostate; 2017 May; 77(6):625-638. PubMed ID: 28144969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer.
    Ylitalo EB; Thysell E; Landfors M; Brattsand M; Jernberg E; Crnalic S; Widmark A; Hultdin M; Bergh A; Degerman S; Wikström P
    Clin Epigenetics; 2021 Jun; 13(1):133. PubMed ID: 34193246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.
    Kohli M; Ho Y; Hillman DW; Van Etten JL; Henzler C; Yang R; Sperger JM; Li Y; Tseng E; Hon T; Clark T; Tan W; Carlson RE; Wang L; Sicotte H; Thai H; Jimenez R; Huang H; Vedell PT; Eckloff BW; Quevedo JF; Pitot HC; Costello BA; Jen J; Wieben ED; Silverstein KAT; Lang JM; Wang L; Dehm SM
    Clin Cancer Res; 2017 Aug; 23(16):4704-4715. PubMed ID: 28473535
    [No Abstract]   [Full Text] [Related]  

  • 11. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.
    Peacock SO; Fahrenholtz CD; Burnstein KL
    Mol Endocrinol; 2012 Dec; 26(12):1967-79. PubMed ID: 23023561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials.
    Rizzo A; Mollica V; Rosellini M; Marchetti A; Ricci AD; Fiorentino M; Battelli N; Santoni M; Massari F
    Pathol Res Pract; 2021 Jun; 222():153440. PubMed ID: 33857854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs.
    Han D; Labaf M; Zhao Y; Owiredu J; Zhang S; Patel K; Venkataramani K; Steinfeld JS; Han W; Li M; Liu M; Wang Z; Besschetnova A; Patalano S; Mulhearn MJ; Macoska JA; Yuan X; Balk SP; Nelson PS; Plymate SR; Gao S; Siegfried KR; Liu R; Stangis MM; Foxa G; Czernik PJ; Williams BO; Zarringhalam K; Li X; Cai C
    J Clin Invest; 2024 Apr; 134(11):. PubMed ID: 38687617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
    Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
    Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.
    Yamamoto Y; Loriot Y; Beraldi E; Zhang F; Wyatt AW; Al Nakouzi N; Mo F; Zhou T; Kim Y; Monia BP; MacLeod AR; Fazli L; Wang Y; Collins CC; Zoubeidi A; Gleave M
    Clin Cancer Res; 2015 Apr; 21(7):1675-87. PubMed ID: 25634993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of androgen receptor variants in hormone-sensitive prostate cancer xenografts, castration-resistant sublines, and patient specimens according to the treatment sequence.
    Honda M; Kimura T; Kamata Y; Tashiro K; Kimura S; Koike Y; Sato S; Yorozu T; Furusato B; Takahashi H; Kiyota H; Egawa S
    Prostate; 2019 Jun; 79(9):1043-1052. PubMed ID: 30998834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.
    Krause WC; Shafi AA; Nakka M; Weigel NL
    Int J Biochem Cell Biol; 2014 Sep; 54():49-59. PubMed ID: 25008967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients.
    Crnalic S; Hörnberg E; Wikström P; Lerner UH; Tieva A; Svensson O; Widmark A; Bergh A
    Endocr Relat Cancer; 2010 Dec; 17(4):885-95. PubMed ID: 20688881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy.
    Chen X; Bernemann C; Tolkach Y; Heller M; Nientiedt C; Falkenstein M; Herpel E; Jenzer M; Grüllich C; Jäger D; Sültmann H; Duensing A; Perner S; Cronauer MV; Stephan C; Debus J; Schrader AJ; Kristiansen G; Hohenfellner M; Duensing S
    Urol Oncol; 2018 Apr; 36(4):161.e19-161.e30. PubMed ID: 29198908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.